NEW YORK, Feb. 13 - Just three weeks after announcing that its president had left, Deltagen said today that its CEO, William Matthews, had resigned.
Matthews, a co-founder of Deltagen, has served as CEO since 1998.
The office of board chairman Constantine Anagnostopoulos will manage the company until it finds a new CEO, Deltagen said.
The company has been publicly searching for a new CEO since November, after changing course from drug discovery to tools and services, but Matthews was directing day-to-day operations of the transgenic technology company, along with Anagnostopoulos and chief financial officer Richard Hawkins.
Matthews departure is the latest sign that the company, like others in the sector, has been struggling to survive. On Jan. 21, president and chief operating officer Michael Sember left. At the time, GenomeWeb reported that the company had reduced its headcount to 200 and made plans to cut loose its proteomics subsidiary and its